GSK plc

NYSE:GSK

Drug Manufacturers - General

Healthcare
$48.58 -2.56%

-$1.34 today

Market cap
$97.53B
Beta
0.29
P/E (TTM)
13.3
EPS (TTM)
$1.45
Dividend yield
3.48%
52W Low $35.45High $61.70

Volume 2.02M

Average 4.07M

GSK Tax Assets

Deferred tax assets that can reduce taxes payable in future periods.

GSK plcNYSE: GSK

Tax Assets · Q2 FY2026 · quarter ended Jun 2026

Tax assets falls 30.1% from a year ago

Tax assets stood at £6.3B at the end of Q2 FY2026, down 30.1% from a year earlier and down 24.2% from the prior quarter. Over 3 fiscal years it compounded at +4.8% a year.

Context

  • Tax assets amounted to 10.3% of total assets at the end of Q2 FY2026, down 0.8 pp from a year earlier.
  • Tax assets increased in 1 of the last 3 fiscal years.

What to watch

Whether tax assets keeps falling in the next quarterly balance sheet after a -30.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
£6.3B-24.2% QoQ
Last fiscal yearDec 2025
£6.51B-3.7% YoY
Year agoJun 2025
£9.02B-30.1% since
Tax Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-30.1%——
1 year-3.7%——
3-year CAGR+4.8%——
5-year CAGR——
10-year CAGR——

Tax Assets history

GBP · from the balance sheet

Latest · FY2025
6.51B GBP
Year-over-year change
-3.7%
4-year CAGR
-2.0%

Tax Assets vs competitors

How GSK compares with its peers on the latest reported figures

  • Peers report in different currencies, so tax assets is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -30.1% is the 6th highest of 7, against a peer median of +1.3%.
  • Tax assets amounts to 10.3% of total assets for GSK, versus a peer median of 4.0%.
GSK Competitors
Tax Assets for GSK and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NVONovo Nordisk A/SJun 2026DKK 23.67B DKK-0.3%+20.8%4.0%
PFEPfizer Inc.Jun 2026$10.77B USD+4.2%+13.2%5.4%
LLYEli Lilly and CompanyJun 2026$10.03B USD+6.4%+52.8%7.0%
JNJJohnson & JohnsonSep 2026$6.75B USD+1.2%-8.4%3.4%
AZNAstraZeneca PLCSep 2026$6.64B USD——5.5%
GSKGSK plcJun 2026£6.3B GBP-30.1%+4.8%10.3%
NVSNovartis AGJun 2026$5.28B USD+1.4%+39.1%4.3%
MRKMerck & Co., Inc.Jun 2026$0 USD——0.0%
AMGNAmgen Inc.Jun 2026$0 USD——0.0%
SNYSanofiJun 2026€0 EUR-100.0%+17.0%0.0%
Peer median (excluding GSK) —+1.3%+18.9%4.0%

Competitors are the stored peer set for GSK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

GBP
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents5.79B3.72B3.74B3.69B3.39B
Short-term Investments82.62M4.15B2.86B21M8.98M
Net Receivables10.88B6.22B9.44B6B7.75B
Inventory7.83B5.15B7.01B5.67B5.91B
Other Current Assets284.44M1.1B262.61M1.23B420.26M
Total Current Assets25.29B20.77B23.77B17B17.48B
Property, Plant & Equipment (Net)14.45B9.62B12.69B10.07B10.03B
Goodwill14.29B7.05B8.68B6.98B7.01B
Intangible Assets40.74B14.32B18.83B15.52B16.72B
Long-term Investments4.29B(2.61B)2.73B1.21B1.12B
Tax Assets7.07B5.66B7.71B6.76B6.51B
Other Non-current Assets1B5.35B808.22M1.93B2.14B
Total Non-current Assets81.85B39.38B51.45B42.47B43.53B
Total Assets107.14B60.15B75.22B59.46B61.01B
Account Payables6.14B3.87B4.74B3.46B15.35B
Short-term Debt4.88B3.79B3.59B2.18B3.01B
Tax Payables489M471M500M703M0
Deferred Revenue415.82M0283.01M00
Other Current Liabilities17.97B14.1B15.25B14.76B2.5B
Total Current Liabilities32.06B22.81B26.86B21.7B21.35B
Long-term Debt26.76B16.19B18.04B13.7B14.68B
Deferred Tax Liabilities4.82B289M396.46M382M290.49M
Deferred Revenue (Non-current)115.13M83M323.8M165M0
Other Non-current Liabilities13.38B9.83B11.95B9.5B8.69B
Total Non-current Liabilities46.17B27.24B32.05B24.68B23.66B
Total Liabilities78.23B50.05B58.91B46.38B45.02B
Common Stock1.82B1.35B1.72B1.35B1.35B
Retained Earnings13.26B4.36B9.23B7.8B10.19B
Accumulated OCI869.56M02.04B00
Other Stockholders Equity01.45B01.05B1.32B
Minority Interest8.52B(502M)(703.69M)(585M)(420.26M)
Total Equity28.91B10.1B16.31B13.09B15.93B
Total Debt32.74B20.99B22.97B16.99B17.69B
Net Debt26.95B17.26B19.23B13.29B14.3B

GSK plc

NYSE:GSK

Intrinsic Alpha fair value

Locked

Current Price

$48.58

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.